ClinicalTrials.gg
Active, not recruitingNCT06979050Updated Oct 3, 2025

Evaluation of the Ronnie Gardiner Method in Individuals With Stroke in Late Phase of Recovery

An interventional study of The Ronnie Gardiner Method in Stroke, sponsored by Göteborg University. Active, not recruiting at 3 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Göteborg University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 158 studies in Stroke with a site in Sweden — 30 open to participants now, 42 under way, 5 of them phase 3. Stroke · Sweden.

Planned enrollment
77th of 123
80 · median 200
Started
2025
with 8 others
No phase
74 of 158
18 open now
Primary completion
2027-03
later than 16 of 41 live
Registered
142nd of 158
by date
Lead sponsor
9 of 158
Göteborg University

Among the 158 studies in Stroke with a site in Sweden, this one is the 77th largest by planned enrollment of the 123 interventional ones that give a count, is one of 9 that started in 2025, is one of 74 with no phase, reaches primary completion later than 16 of the 41 other live ones, and was the 142nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

30 of the 158 studies in Stroke with a site in Sweden are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Stroke with a site in Sweden, or all of them as a file.
02

Study summary

Stroke is a common condition that often leads to long-term disabilities, significantly affecting individuals' quality of life and imposing substantial societal costs. There is growing evidence that physical rehabilitation can improve motor function, well-being, and quality of life even in the chronic phase after stroke. In recent years, rhythm- and music-based interventions have gained increasing attention as promising tools in neurorehabilitation. The Ronnie Gardiner Method (RGM) is a structured, music-based training method that engages motor, sensory, cognitive, and emotional functions simultaneously. While preliminary studies have shown positive effects of RGM in individuals with Parkinson's disease, there is limited research on its impact in stroke rehabilitation, particularly in the chronic phase.

This randomized controlled multicenter study aims to evaluate the effects of RGM training in individuals aged 18 and older who are more than six months post-stroke. Participants will be randomly assigned to either an intervention group receiving RGM training twice per week for 12 weeks, or to a passive control group. The primary outcome is balance, assessed by the Mini-BESTest. Secondary outcomes include gait, upper limb function, cognitive abilities such as working memory and divided attention, and health-related quality of life. Additionally, qualitative data will be collected to explore participants' and trainers' experiences regarding motivation, engagement, and perceived impact on daily participation. The study is expected to provide valuable evidence on the clinical usefulness of RGM in chronic stroke rehabilitation and its potential to be implemented as part of community-based, cost-effective rehabilitation programs.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Music-based intervention
  • Stroke rehabilitation
  • Ronnie Gardiner Method
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Community-dwelling individuals with stroke that occurred > 6 months ago
  • Cognitive ability corresponding to at least 25 out of 30 points on the (MoCA)
  • Functional disability corresponding to a Modified Rankin Scale (mRS) score of 2-3
  • No assistance required for daily activities during participation (e.g., can independently travel to measurement/training sites and use the restroom)
  • Ability to stand for 2 minutes without support and walk 10 meters with or without assistive devices, but without supervision

Exclusion criteria

Exclusion Criteria:

  • Severe visual and/or hearing impairments that would interfere with study participation
  • Participation in regular sessions with RGM after August 2024
  • Previous experience playing a musical instrument (defined as practicing >1 hour/week in the past 10 years)
  • A score of less than 25 on the (MoCA)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Music-based intervention

    Participants randomized to the intervention group will receive the Ronnie Gardiner Method (RGM), a rhythm- and music-based training program, in group sessions led by a certified instructor. The intervention consists of 60-minute sessions, twice per week, for 12 consecutive weeks. The training incorporates coordinated movements, speech, and rhythm using visual symbols representing limbs and directions, performed to music with varying tempo and complexity. Exercises are designed to improve motor function, balance, coordination, and cognitive engagement. Sessions are conducted primarily in standing to optimize balance effects.

    Behavioral: The Ronnie Gardiner Method

  • No intervention
    Waiting-list

    Waiting list, receiving the same intervention after the final follow-up assessment three months post-intervention.

Interventions

  • BehavioralThe Ronnie Gardiner Method

    The intervention involves participants performing coordinated movements while saying specific cue words, synchronized to rhythmic music. The exercises are guided by a visual notation system consisting of 19 colored symbols that represent different body parts and movements. Red symbols indicate movements on the left side of the body, while blue symbols represent the right side. Each symbol corresponds to a specific movement and verbal cue. Exercises are typically performed standing to maximize balance effects and are accompanied by rhythmic, often popular, music to enhance engagement and motivation. Complexity can be increased by adjusting the tempo of the music or combining multiple symbols. Training sessions are conducted in groups, led by certified instructors, twice per week for 12 weeks (60 minutes per session), with an additional home-based practice session each week.

    Also known as: RGM

06

What researchers measure

Primary outcomes

  1. Balance performance measured by the Mini Balance Evaluation Systems Test (Mini-BESTest)

    The mini-BESTest (Mini Balance Evaluation Systems Test) is a shortened version of the BESTest, designed to assess balance and functional mobility, especially in individuals with neurological or musculoskeletal conditions. It focuses on balance deficits across domains like postural control, gait, stability, and anticipatory responses. With 14 items compared to the original 36, the mini-BESTest is quicker to administer, making it more practical for clinical use. It evaluates four main balance systems: * Anticipatory Postural Adjustments: Preparing and adjusting posture for movements. * Reactive Postural Control: Responding to unexpected balance challenges. * Sensory Orientation: Using sensory input (like vision and proprioception) for balance. * Dynamic Gait: Stability and efficiency while walking, including maintaining balance during movement. Minimum score is 0 points, maximum score is 28 points. Higher scores indicate better balance control.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

Secondary outcomes

  1. Concern about falling measured by the Falls Efficacy Scale-International (FES-I)

    FES-I is a tool used to assess a person's confidence in performing daily activities without falling. It consists of 16 questions that cover a range of activities, from walking and bathing to social interactions. The scale helps identify individuals who may have a fear of falling, which can impact their participation in everyday life. Minimum score is 16 points, maximum score is 64 points. A higher score indicates greater concern about falling, and it's commonly used in older adults or individuals at risk of falls to guide interventions aimed at improving balance and reducing fall risk.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  2. Working memory measured by the Memory Test (Immediate and Delayed Recall)

    The test assesses the ability to recall a read text immediately after it is read aloud and after a few minutes, when another test is conducted (delayed recall).

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  3. Cognitive flexibility and inhibitory control measured by the Victoria Stroop Test

    Measures cognitive flexibility, attention, and response inhibition. It involves naming the color of printed words that may or may not match the color they describe, requiring the individual to suppress automatic reading responses. The test is commonly used to assess executive function, particularly in individuals with neurological conditions. It includes three conditions, and outcomes include reaction time and number of errors. Higher interference scores indicate poorer inhibitory control.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  4. Visuospatial memory and organization measured by the Rey-Osterrieth Complex Figure Test

    The Rey-Osterrieth Complex Figure Test is a neuropsychological assessment used to evaluate visuospatial abilities, memory, attention, and executive function. Individuals are asked to copy a complex geometric figure and later reproduce it from memory after a delay. It is commonly used to assess cognitive impairments in various neurological conditions. Scoring is based on accuracy and placement of figure components. Higher scores indicate better visuospatial memory and organizational performance.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  5. Physical performance measured by the Short Physical Performance Battery (SPPB)

    A clinical tool used to assess lower extremity function and mobility in older adults. It includes tests of balance, gait speed, and chair stands to evaluate physical performance. The SPPB is commonly used to predict disability, falls, and overall functional decline. Minimal score is 0 points, maximum score is 12 points. Higher score indicates better physical function.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  6. Functional mobility and gait performance measured by the 10-Meter Walk Test (10MWT)

    The 10-Meter Walk Test (10MWT) is a quick assessment used to measure walking speed over 10 meters at the individual's self-selected pace. It evaluates functional mobility, gait efficiency, and balance. The test is commonly used to monitor progress and predict functional outcomes in people with neurological or musculoskeletal conditions.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  7. Physical capacity including aerobic capacity and endurance measured by the 6-Minute Walk Test (6MWT)

    The 6-Minute Walk Test (6MWT) measures the distance an individual can walk at a self-paced speed over six minutes. It assesses aerobic capacity, endurance, and functional mobility. The test is widely used to evaluate cardiovascular and pulmonary function in clinical and rehabilitation settings. The test measures the distance a person can walk in six minutes on a flat, hard surface, typically a 30-meter course.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  8. Upper extremity function measured by The Observational Drinking Task Assessment

    The Observational Drinking Task Assessment is used to evaluate upper limb function, motor control, and coordination during a simulated drinking task. The individual is observed while reaching for, grasping, and bringing a cup to the mouth. It is often used in neurological rehabilitation to assess functional use of the affected arm. Minimal score is 0 points, maximal score is 15 points. Higher scores indicate worse outcome, i.e., more impairments in the upper extremity.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  9. Finger dexterity and fine motor skills measures by the 9-Hole Peg Test (9HPT)

    The 9-Hole Peg Test is a standard assessment used to measure finger dexterity and fine motor skills. The individual is required to place and remove pegs from a pegboard as quickly as possible. It is commonly used to assess hand function in individuals with neurological conditions, such as multiple sclerosis or stroke.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  10. Health-related quality of life and functional recovery after a stroke measured by the Stroke Impact Scale 16 (SIS-16)

    The Stroke Impact Scale 16 (SIS-16) is a self-reported questionnaire used to assess the health-related quality of life and functional recovery after a stroke. It consists of 16 items that measure various aspects of physical, emotional, and social functioning. The scale helps track recovery progress and guide rehabilitation in stroke survivors. Minimal score is 16 points, and maximum is 80. Higher score indicates a better function and lower impact on everyday life.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  11. Severity of depressive symptoms measured by the Montgomery-Åsberg Depression Rating Scale (MADRS)

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered assessment used to evaluate the severity of depressive symptoms. It consists of 10 items that assess mood, sleep, appetite, and other emotional and physical symptoms associated with depression. The MADRS is commonly used in clinical settings to monitor treatment progress and assess depression severity. Minumum score is 0 points, and maximum score is 60. Higher scores indicate more severe symptoms of depression.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  12. General health-realted quality of life measured by the Research and development (RAND) 36-item health survey

    The RAND-36 is a health survey used to assess an individual's overall health-related quality of life. It consists of 36 items that measure eight domains, including physical functioning, emotional well-being, social functioning, and general health perceptions. The RAND-36 is widely used in both clinical and research settings to evaluate health outcomes across various conditions. Minimal score is 0 points, maximal score is 100 points. Higher values indicate better self-reported health-related quality of life.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

  13. Cost-effectiveness evaluated with the standardized European Quality of Life (EuroQol) questionnaire with 5 dimensions

    The EuroQol 5D 5L (EQ-5D-5L) is a standardized instrument used to assess health-related quality of life. It includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated on five levels of severity. The EQ-5D-5L is commonly used in clinical trials, healthcare evaluations, and to measure the impact of treatments on patients' well-being. Minimal score is 0 on a visual analogue scale, and 100 is maximum. A higher score indicates better health in general. Scores is used to evaluate an interventions cost-effectiveness.

    Time frame: At baseline, at 12 weeks (end of intervention), and at 24 weeks (3-month follow-up)

Other outcomes

  1. Various cognitive domains measured by the Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) is a screening tool used to assess cognitive function and detect mild cognitive impairment. It evaluates various cognitive domains, including memory, attention, language, visuospatial skills, and executive function. The MoCA is commonly used in clinical settings to identify early signs of cognitive decline, such as in Alzheimer's disease or other neurodegenerative conditions. In our study, it will be used as an inclusion criterion. Minimal score is 0 points, maximum score is 30 points. In our study, a score of 25 is required to be included in the study. The MoCA is only used as a screening tool at baseline.

    Time frame: Only at baseline

  2. Participants' enjoyment of the interventions measured by the Physical Activity Enjoyment Scale (PACES)

    The Physical Activity Enjoyment Scale (PACES) is a tool used to assess an individual's enjoyment of physical activity. It consists of several18 items that measure positive and negative feelings associated with engaging in physical exercise. PACES is commonly used in research and clinical settings to understand motivation and promote long-term adherence to physical activity. Minimal score is 18 points, and maximum score is 126 points. Higher score indicates higher enjoyment of the intervention.

    Time frame: After 12 weeks of treatment

07

Study locations

3 sites
  • Folkuniversitetet
    Gothenburg, 41309, Sweden
  • Resurscentrum
    Karlstad, Sweden
  • Neurologiska rehabiliteringskliniken
    Stockholm, Sweden
08

References and documents

Publications

  • Ghai S, Pohl P. Evaluation of the Ronnie Gardiner Method in individuals with stroke in the late phase of recovery: a protocol for a single-blind multicentre randomised controlled trial. BMJ Open. 2026 Feb 4;16(2):e107178. doi: 10.1136/bmjopen-2025-107178. PubMed 41638729 ↗

Related links

Individual participant data

Plan to share: Yes — Upon completion of the study, data will be prepared and made available in accordance with Swedish data protection reulations and the University of Gothenburg's Rules for Research Data Management. In line with these regulations, data containing personal information will be deposited in the Swedish National Data Service repository under a "restricted access" model. Under this model, a description of the data (metadata) together with relevant documentation files will be openly published, while the actual data files will not be directly accessible. Researchers wishing to access the data must submit a request through the repository, and each request will be reviewed before access is granted.

Supporting information: Study protocol, Informed consent form

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 19 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 18, 2025
StartActual
Jul 21, 2025
Primary completionEst.
Mar 15, 2027
CompletionEst.
Jul 31, 2028
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06979050
Collaborators
Karlstad University
Responsible party
Sponsor
First posted
May 18, 2025
Start date
Jul 21, 2025
Primary completion
Mar 15, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 3, 2025

Study contacts

Petra Pohl, PhD
principal investigator · Göteborg University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion